Univariate and multivariate analyses of progression-free survival (PFS) in relation to immune-related adverse events (irAEs), low baseline erythrocyte sedimentation rate (ESR) values, type of chemotherapy, presence of allele A*01 and haplotype A*01 and/or A*02
| PFS | ||
| Univariate | Multivariate | |
| Gender (M vs F) | 0.63 (0.37 to 1.06) p=0.08 | |
| Histology (squamous vs non-squamous) | 1.07 (0.69 to 1.669) p=0.77 | |
| Age (≥68 vs <68 years) | 0.98 (0.65 to 1.50) p=0.94 | |
| Radiotherapy (yes vs no) | 1.13 (0.74 to 1.72) p=0.57 | |
| TKI (yes vs no) | 0.76 (0.45 to 1.29) p=0.31 | |
| irAEs (yes vs no) | 0.48 (0.32 to 0.74) p=0.001 * | 0.34 (0.15 to 0.78) p=0.01* |
| NLR (≥3 vs <3) | 1.51 (0.96 to 2.37) p=0.07 | |
| CRP (≥7 vs <7) | 1.58 (0.92 to 2.73) p=0.10 | |
| ESR (≥39 vs <39) | 1.88 (1.03 to 3.43) p=0.04* | |
| LDH (≥400 vs <400) | 0.87 (0.54 to 1.41) p=0.58 | |
| Type of chemotherapy (Platinum-based vs other) | 1.73 (1.10 to 2.70) p=0.02* | |
| Allele A01 (yes vs no) | 0.51 (0.27 to 0.96) p=0.04* | |
| A01_A02 haplotype | p=0.02* | p=0.04* |
| (A02 vs no A01 or A02) | 0.57 (0.30 to 1.10) | 0.82 (0.36 to 1.86) |
| (A01 vs no A01 or A02) | 0.25 (0.10 to 0.61) | 0.05 (0.01 to 0.39) |
| (A01 & A02 vs no A01 or A02) | 0.72 (0.28 to 1.83) | 1.29 (0.32 to 5.16) |
HR and its 95% CIs are reported. Data from human leukocyte antigen analysis are considered only if correlated with the endpoint of PFS.
CRP, C-reactive protein; LDH, lactate dehydrogenase; NLR, neutrophil–lymphocyte ratio; TKI, tyrosine kinase inhibitor.